Grant ID DP190025
Awarded On February 21, 2019
Title Preclinical Development of a Novel T-ALL Therapeutic Antibody
Program Product Development Research
Award Mechanism Seed Awards for Product Development Research
Institution/Organization Allterum Therapeutics, LLC
Principal Investigator/Program Director Atul Varadhachary
Cancer Sites Leukemia, Lymphoma
Contracted Amount $2,912,313*

*Pending contract negotiation

Lay Summary

Allterum Therapeutics, a Houston, TX based company, is developing a new drug for the treatment of pediatric T-cell acute lymphoblastic leukemia – a common form of childhood cancer. Although current treatments are effective for a majority of children with this disease, approximately 20% of patients experience a recurrence of the disease. Unfortunately, no drugs exist to effectively help patients who experience this relapse.

Our drug is an antibody which is able to much more specifically target and kill cancer cells without the broader side-effects typically observed with conventional chemotherapies. Therefore, Allterum Therapeutics is addressing a major unmet medical need, as our drug is expe...

Read More